Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.
D000368:Aged; D000577:Amides; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001519:Behavior / Q000187:drug effects; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced; D004296:Dopa Decarboxylase / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000037:antagonists & inhibitors; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010906:Pituitary Hormone-Releasing Hormones / Q000037:antagonists & inhibitors*; D010919:Placebos; D011596:Psychomotor Disorders / Q000139:chemically induced; D012893:Sleep Wake Disorders / Q000139:chemically induced
D000577:Amides; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D009842:Oligopeptides; D010906:Pituitary Hormone-Releasing Hormones; D010919:Placebos; D007980:Levodopa; D009074:Melanocyte-Stimulating Hormones; D004296:Dopa Decarboxylase